All articles tagged with #bristol myers squibb
Bristol Myers Squibb (BMS) reported positive Phase 3 results for two experimental drugs, admilparant and RYZ101, as it seeks to offset the impending loss of exclusivity for its blockbuster products Eliquis and Opdivo. While both trials met their primary endpoints, the market reaction was mixed, with BMS stock initially rising before falling, reflecting investor caution regarding safety data and dose efficacy.
Bristol Myers Squibb claims Phase 2 success for a GPRC5D-targeted CAR-T therapy in multiple myeloma, underscoring the potential of this target while noting ongoing questions about durability and outcomes after progression.
Three patients died in Novartis's CD19-directed CAR-T trials due to a dangerous immune reaction, prompting a halt to those programs, with Bristol Myers Squibb pausing a similar therapy as well.
Bristol Myers Squibb has terminated its partnership with Cellares, the cell-therapy manufacturing company, prompting Cellares to reorganize its operations after a comprehensive evaluation.
Bristol Myers Squibb stock rose about 4% premarket after a Financial Times report that BMS and AstraZeneca discussed a potential $400 billion merger, while AstraZeneca ADRs fell. The deal would be one of the largest in pharma history and comes as 2026 sees a wave of big M&A activity, though analysts warned mega-deals can slow R&D productivity and pipeline progress.
Reuters reports AstraZeneca and Bristol Myers Squibb held preliminary talks about a potential merger valued at about $400 billion, which would create one of the world’s largest pharma companies. The status of talks is unclear, and such a deal would face U.S. antitrust scrutiny under the Trump administration and could require divestitures. The companies’ oncology franchises are a focal point, with historical context from Bristol Myers’ Celgene deal cited in analysis.
AstraZeneca and Bristol-Myers Squibb are reportedly in talks to merge, with a combined value near $400 billion that would create one of the world's largest pharma groups; no deal terms have been disclosed and talks could stall. Such a cross-border deal would face antitrust reviews in the US, UK, and EU, with investors awaiting more detail ahead of the Q3 2026 results in late October.
UK drugmaker AstraZeneca and US rival Bristol Myers Squibb are reportedly weighing a merger valued at about $400 billion, potentially the largest deal in history. Talks have been ongoing for months with no commitment or comment from either side, and the deal would reshape both companies’ cancer-drug portfolios and strategic positioning in the pharma industry.
AstraZeneca is in talks with Bristol Myers Squibb about a potential tie-up valued at roughly $400 billion, which would create one of the world's largest drugmakers. Discussions have been ongoing and could materialize soon but may also be delayed or collapse. The deal would reinforce AstraZeneca's US-focused pivot after its NY listing, with both companies keeping comments to themselves as talks proceed.
Bristol Myers Squibb beat expectations on second-quarter adjusted earnings and revenue and lifted its full-year guidance to $49–$50 billion as newer therapies offset declines in legacy drugs; Eliquis grew 21% to $4.48 billion, contributing to the beat and helping lift the stock.
Bristol Myers Squibb says it will build the biopharma industry’s most advanced and energy-efficient AI-powered supercomputer, deepening its collaboration with Nvidia to accelerate drug discovery and development.
Bristol Myers Squibb announced a strategic agreement with Anthropic to deploy Claude across its research, development, manufacturing, commercial and corporate functions, empowering more than 30,000 employees with agentic AI. The rollout centers on Claude Code for engineering and will embed AI agents into priority workflows to accelerate target identification, trial documentation and regulatory submissions, and to speed manufacturing decisions, all while maintaining enterprise governance and secure integrations. This builds on BMS’s multi-year AI investments and a multi-vendor strategy to speed medicine discovery and delivery.
Bristol Myers Squibb and Hengrui Pharmaceutical are pursuing a deal covering 13 assets valued at up to $15.2 billion, underscoring Hengrui’s expanding global pipeline and Western pharma collaborations.
Bristol Myers Squibb bets that Cobenfy, a 30-year-old drug, can become the first approved treatment for psychosis in Alzheimer's disease; its fate hinges on three pivotal trials later this year after a long-ago trial showed promise but was marred by adverse effects, a rescue journey from Eli Lilly to Karuna Therapeutics before landing with BMS.
Bristol Myers Squibb's stock rose over 5% after delaying the results of a clinical trial for Cobenfy, a drug for Alzheimer's disease psychosis, due to enrollment irregularities. The delay, expected to extend the trial completion to 2026, suggests positive trends despite concerns, and the stock's movement reflects investor optimism about the potential market and ongoing development efforts.